Nektar Therapeutics (NKTR)
NASDAQ: NKTR · IEX Real-Time Price · USD
1.420
+0.060 (4.41%)
Apr 23, 2024, 4:00 PM EDT - Market closed
Nektar Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Nektar Therapeutics stock have an average target of 3.50, with a low estimate of 1.00 and a high estimate of 6.00. The average target predicts an increase of 146.48% from the current stock price of 1.42.
Analyst Consensus: Hold
* Price targets were last updated on Mar 6, 2024.
Analyst Ratings
The average analyst rating for NKTR stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 4 | 4 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold Maintains $0.5 → $1 | Hold | Maintains | $0.5 → $1 | -29.58% | Mar 6, 2024 |
| JP Morgan | JP Morgan | Sell Initiates n/a | Sell | Initiates | n/a | n/a | Nov 20, 2023 |
| TD Cowen | TD Cowen | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Nov 9, 2023 |
| Mizuho | Mizuho | Hold Reiterates $6 | Hold | Reiterates | $6 | +322.54% | Aug 7, 2023 |
| Jefferies | Jefferies | Sell → Hold Upgrades $1.5 → $1 | Sell → Hold | Upgrades | $1.5 → $1 | -29.58% | May 10, 2023 |
Financial Forecast
Revenue This Year
68.86M
from 90.12M
Decreased by -23.60%
Revenue Next Year
63.51M
from 68.86M
Decreased by -7.76%
EPS This Year
-0.90
from -1.45
EPS Next Year
-0.73
from -0.90
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 89.6M | 86.0M | 102.6M | 105.0M | 105.0M |
| Avg | 68.9M | 63.5M | 64.8M | 63.3M | 67.0M |
| Low | 21.8M | 22.4M | 23.1M | 23.6M | 30.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.6% | 24.9% | 61.5% | 61.9% | 65.9% |
| Avg | -23.6% | -7.8% | 2.1% | -2.4% | 5.9% |
| Low | -75.9% | -67.4% | -63.6% | -63.6% | -51.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.68 | -0.33 | -0.21 |
| Avg | -0.90 | -0.73 | -0.67 |
| Low | -1.19 | -0.98 | -1.03 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.